Morgan Stanley raised the firm’s price target on Centessa to $11 from $8 and keeps an Equal Weight rating on the shares. The firm updated its view to include a market model for ORX750 in narcolepsy type 1, with a projected $1.86B in unadjusted peak net sales by 2036, or about $556M risk-adjusted peak net sales with a 30% probability of success. The first clinical data is expected from ORX750 in the second half of this year, notes the firm, which sees shares being up 20%-30% with positive results and down 30%-40% with negative results.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTA:
- Centessa Pharmaceuticals Announces Executive Team Reshuffle and New CFO
- Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer
- Centessa appoints Crowley as CFO, Weinhoff as CBO
- Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
- Centessa’s Drug Development Hurdles: FDA Fast Track No Guarantee for Hemophilia B Treatment Approval